KV Pharmaceutical Reaches Agreement with U.S. Department of Justice
February 25, 2010
KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva™
January 11, 2010
KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director
January 07, 2010
KV Pharmaceutical Receives Permission from NYSE For its Securities to Continue Trading on the NYSE until March 31, 2010
December 22, 2009
KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent
December 15, 2009
KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet
December 02, 2009
KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments
November 13, 2009
KV Pharmaceutical Divests ANDA for Generic Version of Duac®
September 21, 2009
KV Pharmaceutical Receives Stockholder Action by Written Consent
September 15, 2009
KV Pharmaceutical Receives Letter from NYSE Regarding Delayed Filing of its 2009 Annual Report on Form 10-K
June 22, 2009
|
|
The Press Releases shown in this section of the Web
site are presented for archival purposes only. The Press Releases are presented as they were
originally released. The Company makes no claim that the information contained in these materials
is currently accurate or is presented in a manner that would be appropriate for dissemination as
a press release at the present time. See
also KV
Pharmaceutical Company Web Site Terms of Use and Legal Restrictions and Product
Disclaimer. |
|